Vaccines and Immunotherapy — Revision Notes

⚡ 30-Second Revision

Key Facts:

Vaccines: — Prophylactic, prime immune system. Types: Live attenuated (MMR, OPV), Inactivated (Covaxin, IPV), Subunit (Hep B), mRNA (Pfizer, Moderna), Viral Vector (Covishield, Sputnik V).
Immunotherapy: — Therapeutic, modulate immune system. Types: Monoclonal Antibodies (Rituximab, Pembrolizumab), Checkpoint Inhibitors (PD-1/CTLA-4), CAR-T Cell Therapy.
India: — Largest vaccine producer (SII, Bharat Biotech). Mission Indradhanush (immunization). National Vaccine Policy 2011. CDSCO (regulator). Vaccine Maitri (diplomacy).
COVID-19: — mRNA (ultra-cold), Viral Vector (refrigerator stable), Inactivated (traditional).
CAR-T: — Personalized, for blood cancers, risk of Cytokine Release Syndrome (CRS). First indigenous CAR-T (NexCAR19) approved in India (2023).
Ethics: — Informed consent, equitable access, pharmacovigilance (AEFI), vaccine hesitancy.

2-Minute Revision

Vaccines prevent disease by introducing weakened or partial pathogen components to train the immune system, leading to antibody and memory cell production. Key types include live attenuated (e.g., MMR, requiring cold chain, not for immunocompromised), inactivated (e.

g., Covaxin, safer but less robust immunity), subunit (e.g., Hepatitis B, very safe), mRNA (e.g., Pfizer, Moderna, rapid development, ultra-cold storage), and viral vector (e.g., Covishield, Sputnik V, refrigerator stable).

Immunotherapy treats existing diseases, primarily cancer, by enhancing the body's immune response. Major approaches are monoclonal antibodies (mAbs) like Rituximab, checkpoint inhibitors (e.g., Pembrolizumab) that release immune 'brakes,' and CAR-T cell therapy, a personalized treatment where patient's T cells are engineered to target cancer, with a risk of Cytokine Release Syndrome (CRS).

India is a global leader in vaccine manufacturing (SII, Bharat Biotech), with initiatives like Mission Indradhanush for immunization and 'Vaccine Maitri' for diplomacy. Recent breakthroughs include indigenous mRNA vaccines and CAR-T cell therapy approvals in India.

Ethical considerations like informed consent, equitable access, and pharmacovigilance (AEFI) are crucial for both.

5-Minute Revision

Vaccines and immunotherapy are cornerstones of modern medicine, both leveraging the immune system. Vaccines are prophylactic, preventing infectious diseases by priming the immune system with antigens.

The diverse platforms include: Live Attenuated (weakened pathogen, strong immunity, e.g., MMR, but not for immunocompromised, cold chain sensitive); Inactivated (killed pathogen, safer, e.g., Covaxin, but weaker immunity, needs boosters); Subunit/Toxoid (specific components, very safe, e.

g., Hepatitis B, DTaP); mRNA (genetic instructions for antigen, rapid, strong immunity, e.g., Pfizer/Moderna, but ultra-cold chain); and Viral Vector (harmless virus delivers genetic material, strong immunity, e.

g., Covishield/Sputnik V, refrigerator stable). Understanding these differences is vital for Prelims.

Immunotherapy is therapeutic, primarily for cancer, by modulating the immune response. Key types: Monoclonal Antibodies (mAbs) (target specific molecules, e.g., Rituximab, Trastuzumab); Checkpoint Inhibitors (block immune 'brakes' like PD-1/CTLA-4, e.g., Pembrolizumab, Nivolumab, unleashing T cells); and CAR-T Cell Therapy (patient's T cells genetically engineered to target cancer, highly personalized, e.g., for blood cancers, but carries risk of Cytokine Release Syndrome).

India's role is significant: it's the world's largest vaccine producer (Serum Institute, Bharat Biotech), crucial for global health security. Initiatives like Mission Indradhanush aim for universal immunization, while the National Vaccine Policy 2011 guides strategy.

The Drugs and Cosmetics Act, 1940, and CDSCO regulate these products. 'Vaccine Maitri' showcased India's vaccine diplomacy. Recent developments include COVID-19 vaccine platforms, indigenous mRNA initiatives, and the approval of India's first CAR-T cell therapy (NexCAR19).

Ethical and policy challenges include informed consent, equitable access, vaccine hesitancy, and robust pharmacovigilance (AEFI systems). For Mains, analyze these scientific advancements within India's socio-economic and geopolitical context, connecting them to 'Atmanirbhar Bharat' and public health policy.

Prelims Revision Notes

1
Vaccine Types & Mechanisms:

* Live Attenuated: Weakened live pathogen. Mimics natural infection. Strong, long-lasting immunity (cellular + humoral). Examples: MMR, OPV, BCG, Varicella, Yellow Fever. Caution: Not for immunocompromised/pregnant.

Cold chain critical (some -20°C). * Inactivated: Killed whole pathogen. Cannot replicate. Safer. Primarily humoral immunity. Examples: IPV, Hepatitis A, Rabies, Covaxin. Multiple doses often needed.

Storage: 2-8°C. * Subunit/Toxoid/Conjugate: Specific parts (proteins, polysaccharides, inactivated toxins). Very safe. Examples: Hepatitis B, HPV, DTaP, Pneumococcal. May need adjuvants. Storage: 2-8°C.

* mRNA: Genetic code for antigen. Host cells produce antigen. Rapid development. Strong cellular + humoral. Examples: Pfizer-BioNTech, Moderna. Challenge: Ultra-cold storage (-70°C to -20°C).

* Viral Vector: Harmless virus delivers DNA. Host cells produce antigen. Strong cellular + humoral. Examples: Covishield, Sputnik V. Storage: 2-8°C.

1
Immunotherapy Basics:

* Monoclonal Antibodies (mAbs): Lab-made antibodies. Target specific molecules. Examples: Rituximab (CD20), Trastuzumab (HER2), Pembrolizumab (PD-1). * Checkpoint Inhibitors: Block 'brakes' (PD-1, CTLA-4) on T cells. Unleash anti-tumor immunity. Examples: Pembrolizumab, Nivolumab. * CAR-T Cell Therapy: Patient's T cells engineered with Chimeric Antigen Receptor. Personalized. For blood cancers (ALL, DLBCL). Risk: Cytokine Release Syndrome (CRS), neurotoxicity.

1
India Specifics:

* Manufacturers: Serum Institute of India (SII - largest by dose), Bharat Biotech. * Policies/Programs: National Vaccine Policy 2011, Mission Indradhanush (universal immunization). * Regulatory: CDSCO (Central Drugs Standard Control Organisation) under Drugs and Cosmetics Act, 1940. * Diplomacy: Vaccine Maitri (COVID-19 vaccine supply). * Indigenous: Covaxin (inactivated), GEMCOVAC-19 (mRNA, under development), NexCAR19 (CAR-T, approved 2023).

1
Key Concepts: — Herd Immunity (1-1/R0), Cold Chain, Adjuvant, AEFI (Adverse Events Following Immunization), Efficacy vs. Effectiveness, Antibody Waning, ADE (Antibody-Dependent Enhancement - not significant for COVID-19 vaccines).

Mains Revision Notes

1
Vaccine Technology & Pandemic Preparedness:

* Advancements: Shift from traditional (inactivated, live attenuated) to modern (mRNA, viral vector) platforms. Emphasize speed, adaptability, and precision. * Implications: Rapid response to emerging pathogens, ability to adapt to variants, potential for broad-spectrum vaccines. * Challenges: Cold chain for mRNA, manufacturing scalability, equitable access globally.

1
India's Vaccine Ecosystem & 'Atmanirbhar Bharat':

* Manufacturing Prowess: India as 'pharmacy of the world,' role of SII, Bharat Biotech. Strategic importance of indigenous capacity. * Policy Framework: National Vaccine Policy 2011, Mission Indradhanush.

CDSCO's role in regulation (Drugs & Cosmetics Act, New Drugs & Clinical Trials Rules 2019). * Vaccine Diplomacy: 'Vaccine Maitri' - soft power, humanitarian aid, geopolitical influence. * Indigenous R&D: Importance of developing own mRNA, CAR-T (NexCAR19) to reduce dependence and ensure health security.

1
Immunotherapy in Cancer Treatment:

* Paradigm Shift: From chemotherapy/radiation to harnessing body's own immune system. * Mechanisms: Checkpoint inhibitors (unleashing T cells), Monoclonal Antibodies (targeted attack), CAR-T (personalized cell therapy).

* CAR-T in India: Breakthrough with NexCAR19. Discuss process, indications (blood cancers), and severe adverse events (Cytokine Release Syndrome, neurotoxicity). * Challenges: High cost, complex logistics, resistance mechanisms, limited efficacy in solid tumors, ethical concerns of access and affordability.

1
Ethical, Policy & Governance Issues:

* Informed Consent & Liability: Critical for clinical trials and novel therapies. * Equitable Access: Global North-South divide, domestic disparities. Role of WHO, COVAX. * Vaccine Hesitancy: Causes (misinformation, trust deficit), strategies (risk communication, community engagement). * Pharmacovigilance: Robust AEFI systems for safety monitoring and public trust. * Bioethics & Regulations : Balancing innovation with safety and ethical considerations.

Vyyuha Quick Recall

VACCI-IMMUNE for Vaccines & Immunotherapy:

Vaccine Always Combats Cancer Infections - Immunotherapy Modulates My Unique Natural Energy.

VACCINE TYPES (LIMS-VV):

Live Attenuated
Inactivated
MRNA
Subunit
Viral Vector

IMMUNOTHERAPY (CAR-CHECK-MONO):

CAR — T Cell Therapy
CHECKpoint Inhibitors
MONOclonal Antibodies

INDIA's VACCINE ROLE (MIMIC):

Manufacturing Hub
Indradhanush (Mission)
Maitri (Vaccine Diplomacy)
Indigenous R&D
CDSCO (Regulation)

Visual Memory Aids:

1
Vaccine Cold Chain Infographic: — A diagram showing different temperature zones for vaccine storage (e.g., -70°C for mRNA, 2-8°C for others) from factory to arm.
2
CAR-T Cell Therapy Workflow: — A flowchart illustrating the steps: apheresis -> T-cell engineering -> expansion -> infusion -> cancer cell killing.
3
Immune Checkpoint Inhibitor Diagram: — A visual showing T-cell with 'brakes' (PD-1) and cancer cell with 'accelerator' (PD-L1), and how inhibitors block the interaction to 'release the brake'.